Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence
The COVID-19 pandemic has encouraged the repurposing of existing drugs as a shorter development strategy in order to support clinicians with this difficult therapeutic dilemma. There is evidence to support the theory that some antidepressants can reduce concentrations of different cytokines in human...
Main Authors: | Marta Mas, Juan Antonio García-Vicente, Anaïs Estrada-Gelonch, Clara Pérez-Mañá, Esther Papaseit, Marta Torrens, Magí Farré |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/14/4038 |
Similar Items
-
Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19
by: Nicolas Hoertel, et al.
Published: (2022-10-01) -
Transcriptomic Studies of Antidepressant Action in Rodent Models of Depression: A First Meta-Analysis
by: El Chérif Ibrahim, et al.
Published: (2022-11-01) -
Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19
by: Mahsa Asadi Anar, et al.
Published: (2022-11-01) -
Carbon supported ternary layered double hydroxide nanocomposite for Fluoxetine removal and subsequent utilization of spent adsorbent as antidepressant
by: Samar M. Mahgoub, et al.
Published: (2024-02-01) -
Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort
by: Catherine L. Clelland, et al.
Published: (2022-01-01)